XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Xeris Biopharma Holdings, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 86.6%
- Operating margin
- 10.9%
- Net margin
- -5.1%
- Return on equity, FY2025
- -7.0%
Financial strength
- Current ratio
- 1.45
- Debt to equity
- -25.95
- Debt to assets
- 61.3%
- Cash to current liabilities
- 64.2%
Valuation
- P/E ratio
- –
- Price to sales
- 5.64
- Price to book
- –
- Dividend yield
- –